Objective of the project

 IMBA is a health technology assessment project. It will analyse how specific new developments in biomedicine which are often summarized under the term “toxicogenomics” will transform the present risk management framework. The focus of our research will be on the impacts – both challenges and opportunities – on risk characterization, risk perception, and risk communication.

IMBA will

• conduct a research programme involving research groups and programmes inside the HGF, in close collaboration with German universities as well with international centers of excellence;
• add critical mass to social science research on the impacts of toxicogenomic-based risk assessment for policymaking. This will be accomplished through a focussed and coherent research programme based on interdisciplinary collaboration between life science and social science;
• contribute to the public debate on the impacts of toxicogenomics for risk assessment through dialogue with various stakeholders; and
• foster international collaboration through international networks and conferences.